GBT sickle cell trial hits endpoint ahead of NDA filing

GBT sickle cell trial hits endpoint ahead of NDA filing

Source: 
Fierce Biotech
snippet: 

Global Blood Therapeutics has shared updated data on the sickle cell disease trial it hopes will secure FDA approval of voxelotor. The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo, resulting in the trial hitting its primary endpoint.